Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics (Nasdaq: AUTL) granted inducement stock options totaling 113,650 ADS to 22 employees under its 2025 Inducement Plan, with a grant date of January 26, 2026 and an exercise price of $1.46 per share.
Autolus Therapeutics (Nasdaq: AUTL) granted inducement stock options totaling 113,650 ADS to 22 employees under its 2025 Inducement Plan, with a grant date of January 26, 2026 and an exercise price of $1.46 per share. Each option has a 10-year term and vests over four years (25% after one year, then monthly over 36 months), subject to continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
This announcement details inducement stock option grants covering 113,650 ADSs to 22 new employees a...
Analysis
This announcement details inducement stock option grants covering 113,650 ADSs to 22 new employees at an exercise price of $1.46, vesting over four years. It follows recent milestones in revenue growth, manufacturing strategy, and clinical data. The grants align with ongoing scaling of Autolus’ commercial operations. Investors may watch future disclosures on hiring, operating performance, and additional equity awards to gauge how workforce expansion supports the company’s commercial and clinical objectives.
Key Figures
Inducement options:113,650 ADSsEmployees granted:22 employeesExercise price:$1.46 per share+5 more
Inducement options
113,650 ADSs
Stock options granted under 2025 Inducement Plan
Employees granted
22 employees
Recipients of inducement stock option awards
Exercise price
$1.46 per share
Equal to AUTL closing price on Jan 23, 2026
Option term
10 years
Maximum life of each inducement stock option
Vesting cliff
25% after 1 year
Initial vesting on first anniversary of grant date
Appointment of Ryan Richardson with capital markets and M&A experience.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4), american depositary shares, stock option, exercise price, +1 more
5 terms
nasdaq listing rule 5635(c)(4)regulatory
"inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
american depositary sharesfinancial
"granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
stock optionfinancial
"granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise pricefinancial
"an exercise price of $1.46 per share, which is equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the Company’s 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a grant date of January 26, 2026, and an exercise price of $1.46 per share, which is equal to the closing price of Autolus’ common stock on January 23, 2026. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter, subject to the employee's continued service with Autolus through the applicable vesting dates.
About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Autolus (AUTL) announce on February 4, 2026 about inducement stock options?
Autolus announced inducement grants of 113,650 ADS to 22 employees with a $1.46 exercise price. According to Autolus, the options were granted January 26, 2026 and vest over four years with a ten-year term.
How do the inducement options for AUTL vest and what is the exercise price?
The options vest 25% after one year, then monthly over 36 months, and have a 10-year term. According to Autolus, the exercise price is $1.46, equal to the January 23, 2026 closing price.
Why did Autolus grant stock options under Nasdaq Listing Rule 5635(c)(4)?
Autolus granted the awards as inducements to new employees in accordance with Nasdaq rules. According to Autolus, the grants were made as material inducements to employment under Rule 5635(c)(4).
How many employees received inducement awards from Autolus and how many shares are covered?
Autolus granted inducement options to 22 employees covering an aggregate of 113,650 ADS. According to Autolus, each ADS represents one ordinary share for purposes of the award count.
What are the potential shareholder effects of Autolus' inducement grants (AUTL)?
The grants increase outstanding option rights by 113,650 ADS, which may modestly dilute shareholders if exercised. According to Autolus, the awards are standard inducement grants subject to vesting and exercise terms.
